Skip to main content

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.
Subject
IMM Ann: Immutep Quarterly Activities Report and Appendix 4C

IMM Ann: Notification of cessation of securities - IMM

IMM Ann: TACTI-003 trial 50% enrolment milestone has been achieved

IMM Ann: Update on MBC trial design following successful FDA meeting

IMM Ann: Change of Director's Interest Notice L Turnbull

IMM Ann: Change of Director's Interest Notice - P Meyers

IMM Ann: Change of Director's Interest Notice - R Howard

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Notification regarding unquoted securities - IMM

IMM Ann: Notification regarding unquoted securities - IMM

IMM Ann: Proposed issue of securities - IMM

IMM Ann: Commercial Scale in Manufacturing of Efti Achieved

IMM Ann: GMP Manufacturing Process Developed for IMP761 LAG-3 Agonist

IMM Ann: Immutep enters 2nd collaboration with Pfizer and Merck KGaA

IMM Ann: Results of Meeting

IMM Ann: Immutep AGM 2022 - CEO's Presentation

IMM Ann: Immutep AGM 2022 - Chairman's Address

IMM Ann: Immutep Investor Update

IMM Ann: Immutep receives A$1 million R&D Tax Incentive

IMM Ann: Immutep Webcast to discuss clinical data presented at SITC

IMM Ann: TACTI-002 data presented at SITC for Efti in 1st line NSCLC

IMM Ann: INSIGHT-003 triple combination data presented at SITC 2022

IMM Ann: New Patents Granted in Japan and South Korea for Efti

IMM Ann: Abstract for Efti selected for SITC 2022 Press Conference

IMM Ann: Late Breaking Abstract accepted for SITC Oral Presentation

IMM Ann: Immutep Corporate Presentation

IMM Ann: Immutep to Participate in Two Upcoming Investor Conferences

IMM Ann: Annual Report filed on Form 20-F with SEC

IMM Ann: Change of Registry Address

IMM Ann: Independent DMC recommends to continue TACTI-003 as planned

IMM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMM Ann: Notice of Annual General Meeting/Proxy Form

IMM Ann: Appendix 4G and Corporate Governance Statement

IMM Ann: Annual Report to shareholders

IMM Ann: Change in substantial holding

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Ceasing to be a substantial shareholder from AEF

IMM Ann: Abstracts accepted for Presentation at SITC 2022

IMM Ann: Change of Director's Interest Notice - P Meyers

IMM Ann: Change of Director's Interest Notice - M Voigt

IMM Ann: Change of Director's Interest Notice - F Triebel

IMM Ann: Fast Track granted by US FDA for Efti in 1st line NSCLC

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Becoming a substantial holder from AEF

IMM Ann: Immutep to Participate in Two Upcoming Investor Conferences

IMM Ann: Immutep Receives A$2.7 million R&D French Tax Incentive

IMM Ann: 2022 AGM & Key Dates

IMM Ann: Clinical Development Update for Eftilagimod Alpha

IMM Ann: Initial Director's Interest Notice - Frederic Triebel

IMM Ann: Immutep Appoints LAG-3 Pioneer Dr Frederic Triebel to Board

Register to track IMM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMU
MSB
OPT
PAR
PYC
RAC
TLX